Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 2temsirolimus 1pegfilgrastim 1nintedanib 1ixabepilone 1cediranib 1brivanib 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1Metformin 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Epothilones 1Doxorubicin 1Brachytherapy 1AZD 6244 1ALK1-Fc fusion protein, human 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × MK 2206 × Clear all
NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 9 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡